Featured Stock for Investors: Immunomedics Inc. (IMMU)

Cornelia Mascio
Novembre 16, 2017

California State Teachers Retirement System now controls 163,599 shares with a value of $2,287,000. The stock declined 1.50% or $0.46 reaching $30.22 on the news. About 515,802 shares traded.

Immunomedics, Inc. (NASDAQ:IMMU) shares were falling 19% yesterday after abstracts surfaced at the yearly San Antonio Breast Cancer Symposium (SABCS), with one abstract particularly disappointing the biotech-verse. TD Asset Management Inc. now owns 150,400 shares of the biopharmaceutical company's stock worth $1,328,000 after acquiring an additional 18,200 shares in the last quarter. About 1.58M shares traded. It has outperformed by 59.56% the S&P500.

Investors sentiment decreased to 1.41 in Q2 2017. Its down 0.05, from 1.46 in 2017Q1.

As of the end of the quarter Alliancebernstein L.P. had sold 22,400 shares trimming its holdings by 12.6%. 30 funds opened positions while 46 raised stakes.

U.S. based company Immunomedics, Inc. (NASDAQ:IMMU) for 31,635 shares. (NASDAQ:IMMU) for 73,397 shares. Rhumbline Advisers accumulated 123,491 shares. Wells Fargo And Mn holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 298,031 shares.

The most recent non open market insider trade was completed by AGHAZADEH BEHZAD on 08/24/2017, and was a acquisition of 4.25 million shares with a final price of $0.

TRADEMARK VIOLATION WARNING: "Immunomedics, Inc". (NASDAQ:IMMU). Stephens Ar holds 0% or 13,000 shares.

Venbio Select Advisor Llc reported SC 13D/A form with the SEC for Immunomedics Inc.

IMMU has been the topic of several research reports. The company has a debt-to-equity ratio of -0.29, a quick ratio of 0.74 and a current ratio of 0.74.

Immunomedics Inc stake is new for [reportingPerson]. Therefore 67% are positive. Immunomedics had 13 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies downgraded Immunomedics, Inc. Jefferies has "Hold" rating and $1.50 target. For the quarter, shares are performing at 39.10%. IMMU has a 1-week performance of 9.58%. (NASDAQ:IMMU) has "Buy" rating given on Tuesday, September 19 by Jefferies. The third largest holder is Price T Rowe Associates Inc /Md/, which now holds $74 million worth of this stock and that ownership represents almost 6.98% of its market capitalization.

For the Current Quarter, the growth estimate for Immunomedics Inc.is 47.8%, while for the Next Quarter the stock growth estimate is 76.4%. Jefferies maintained it with "Buy" rating and $900 target in Friday, June 9 report.

Jefferies Group LLC raised the price target on October 9 changing the forecast from $14.00 to $16.00 and issued a "Buy" rating. The company was maintained on Thursday, August 17 by Jefferies. It also upped Ishares Tr (IGF) stake by 11,095 shares and now owns 66,660 shares.

Analysts await Immunomedics, Inc.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Wednesday, August 16th. As of the latest earnings report the EPS was $-2.24 with 152.02M shares now outstanding. The business had revenue of $0.64 million during the quarter, compared to analyst estimates of $0.75 million. The volume of MET witnessed a shift from 3.48 million shares, based on a 50-day average, to 4.87 million shares. Point72 Asset Management LP has 0.12% invested in Huntsman Corporation (NYSE:HUN) for 823,000 shares. Eam Limited Co has 507,114 shares. Swift Run Management Lc stated it has 532,313 shares or 7.93% of all its holdings. Engineers Gate Manager LP owns 53,745 shares or 0.13% of their USA portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE